Dexmedetomidine as an Analgesic Agent with Neuroprotective Properties: Experimental and Clinical Aspects
محل انتشار: شانزدهمین کنگره بین المللی صرع
سال انتشار: 1398
نوع سند: مقاله کنفرانسی
زبان: انگلیسی
مشاهده: 508
نسخه کامل این مقاله ارائه نشده است و در دسترس نمی باشد
- صدور گواهی نمایه سازی
- من نویسنده این مقاله هستم
استخراج به نرم افزارهای پژوهشی:
شناسه ملی سند علمی:
EPILEPSEMED16_028
تاریخ نمایه سازی: 28 بهمن 1398
چکیده مقاله:
Dexmedetomidine (dexdor or precedex®) is considered as a sedative agent that is widely used as an adjuvant in general anesthesia and critical care medicine practice. There are many evidences indicating its neuroprotective properties especially in various ischemic and hemorrhagic brain injury models of animals. Clinical trials have shown that dexmedetomidine (DEX) can improve outcome of intensive care unit (ICU) patients. Also, DEX is appropriate for use as a non-opioid analgesic therapy whenever minimizing opioid-related side effects is necessary. The underlying mechanism of this drug is related to the activation of alpha-2 adrenergic receptors, causing inhibition of C-fibers and Aα-fibers in the peripheral nervous system. Alpha-2 adrenergic receptors centrally (in the locus coeruleus) prevent nociceptive neurotransmission through the spinal cord. Alpha-2 adrenergic receptors also presynaptically inhibit the release of norepinephrine, which disturbs depolarization and the pain signaling. In addition, recent studies indicate that in neurons, synthesis and release of acetylcholine and nitric oxide are affected by DEX that could be involved in the regulation of analgesic activity of the drug. Apart from the beneficial effects of the drug on the nervous system, there are potential adverse effects, such as hypotension and bradycardia, which can be treated pharmacologically and must be taken into consideration by clinicians.
کلیدواژه ها:
نویسندگان
Hooman Bozorgi
Department of Pharmacology, School of Medicine, Semnan University of Medical Sciences, Semnan, Iran
Melika Zamani
School of Pharmacy, Pharmaceutical Sciences Branch, Islamic Azad University, Tehran, Iran
Maryam Nankali
Department of Pharmacology, School of Medicine, Semnan University of Medical Sciences, Semnan, Iran